Authors:

Sumithra Urs, Sheri Barnes, Stacey Roys, and Maryland Rosenfeld Franklin

Year:

2019

AACR Annual Meeting

POSTER | ID8-Luc Syngeneic Ovarian Cancer Model for Preclinical Evaluation of Immunomodulatory Molecules (PDF)

POSTER | ID8-Luc Syngeneic Ovarian Cancer Model for Preclinical Evaluation of Immunomodulatory Molecules (PDF)

Introduction and Background

  • Ovarian cancer (OC) is a gynecological malignancy with a high mortality rate of over 14,000 deaths annually in the US. Even though ~80% of OC patients initially go into remission after 1st line treatment (surgery & chemotherapy), more than 60% relapse within 16–18 months.
  • Low neoantigen burden and the immunologically “cold” nature of OC makes it a challenging malignancy. Recent success with immunotherapies in other cancers provides some hope for ovarian cancer patients. One of the most promising data reported that the presence of tumor infiltrating lymphocytes positively correlates with improved survival of OC patients.
  • As novel methods such as immunotherapy and/or combination therapies are essential to improve clinical outcome of patients, characterization of relevant murine models are needed. This work evaluates the ID8-Luc murine ovarian carcinoma model and tests sensitivity to immunomodulatory agents.
  • We have established the ID8 murine ovarian surface epithelial carcinoma cell line derived from C57BL/6 mice as a preclinical syngeneic model to track and monitor disease progression and therapeutic outcomes. Our model relies on the intraperitoneal delivery of luciferase-expressing ID8 cells to mimic aspects of human disease.